Cancer Epidemiology Biomarkers & Prevention, Vol 4, Issue 7 703-707, Copyright © 1995 by American Association for Cancer Research

ARTICLES

Aspirin and other nonsteroidal anti-inflammatory drugs and risk of colorectal adenomatous polyps among endoscoped individuals

ME Martinez, RS McPherson, B Levin and JF Annegers
University of Texas-Houston Health Science Center, School of Public Health 77225, USA.

Most epidemiological evidence supports the inverse association between use of aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) and colorectal cancer. Few studies have investigated the relation between use of aspirin and other NSAIDs and adenomatous polyps, which are recognized as precursors of colorectal cancer. We examined the association of adenomatous polyps and the dose and duration of use of aspirin and other NSAIDs in a case-control study of dietary risk factors for colorectal adenomatous polyps. The study population comprised 157 case and 480 control individuals who underwent an endoscopy at collaborating gastroenterology clinics in Houston, TX. Face-to-face interviews were conducted to obtain risk factor data that included information on frequency and duration of use of aspirin and other NSAIDs. Compared to the nonusers, the multivariate odds ratios for individuals who took aspirin and other NSAIDs on a weekly basis and for those who took these once/day or more were 0.77 (95% confidence interval, 0.39-1.55) and 0.36 (95% confidence interval, 0.20-0.63), respectively. Compared to the nonusers, the odds ratio for individuals who used aspirin and other NSAIDs for <5 years was 0.39 (95% confidence interval, 0.39-1.55) and 0.36 (95% confidence interval, 0.20-0.71), and for those who used these for 5 years or more, the odds ratio was 0.60 (95% confidence interval, 0.32-1.14). The results of this study suggest that aspirin and other NSAIDs are associated with a decreased risk for adenomatous polyps. Limited dose-response analyses found that the point estimate decreased with the frequency but not the duration of use of aspirin and other NSAIDs.

This article has been cited by other articles:

				X. Zuo, L. Shen, J.-P. Issa, O. Moy, J. S. Morris, S. M. Lippman, and I. Shureiqi 15-Lipoxygenase-1 transcriptional silencing by DNA methyltransferase-1 independently of DNA methylation FASEB J, June 1, 2008; 22(6): 1981 - 1992. [Abstract] [Full Text] [PDF]

				A. Bardia, J. O. Ebbert, R. A. Vierkant, P. J. Limburg, K. Anderson, A. H. Wang, J. E. Olson, C. M. Vachon, and J. R. Cerhan Association of Aspirin and Nonaspirin Nonsteroidal Anti-inflammatory Drugs With Cancer Incidence and Mortality J Natl Cancer Inst, June 6, 2007; 99(11): 881 - 889. [Abstract] [Full Text] [PDF]

				A. Rostom, C. Dube, G. Lewin, A. Tsertsvadze, N. Barrowman, C. Code, M. Sampson, and D. Moher Nonsteroidal Anti-inflammatory Drugs and Cyclooxygenase-2 Inhibitors for Primary Prevention of Colorectal Cancer: A Systematic Review Prepared for the U.S. Preventive Services Task Force Ann Intern Med, March 6, 2007; 146(5): 376 - 389. [Abstract] [Full Text] [PDF]

				A. Mahipal, K. E. Anderson, P. J. Limburg, and A. R. Folsom Nonsteroidal Anti-inflammatory Drugs and Subsite-Specific Colorectal Cancer Incidence in the Iowa Women's Health Study. Cancer Epidemiol. Biomarkers Prev., October 1, 2006; 15(10): 1785 - 1790. [Abstract] [Full Text] [PDF]

				M. Allison, C. Garland, R. Chlebowski, M. Criqui, R. Langer, L. Wu, H. Roy, A. McTiernan, L. Kuller, and for the Women's Health Initiative Investigators The Association between Aspirin Use and the Incidence of Colorectal Cancer in Women Am. J. Epidemiol., September 15, 2006; 164(6): 567 - 575. [Abstract] [Full Text] [PDF]

				V. M. Chia, P. A. Newcomb, J. Bigler, L. M. Morimoto, S. N. Thibodeau, and J. D. Potter Risk of Microsatellite-Unstable Colorectal Cancer Is Associated Jointly with Smoking and Nonsteroidal Anti-inflammatory Drug Use. Cancer Res., July 1, 2006; 66(13): 6877 - 6883. [Abstract] [Full Text] [PDF]

				M. Abdelrahim, C. H. Baker, J. L. Abbruzzese, and S. Safe Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation. J Natl Cancer Inst, June 21, 2006; 98(12): 855 - 868. [Abstract] [Full Text] [PDF]

				M. Abdelrahim and S. Safe Cyclooxygenase-2 Inhibitors Decrease Vascular Endothelial Growth Factor Expression in Colon Cancer Cells by Enhanced Degradation of Sp1 and Sp4 Proteins Mol. Pharmacol., August 1, 2005; 68(2): 317 - 329. [Abstract] [Full Text] [PDF]

				G. J. Kelloff, R. L. Schilsky, D. S. Alberts, R. W. Day, K. Z. Guyton, H. L. Pearce, J. C. Peck, R. Phillips, and C. C. Sigman Colorectal Adenomas: A Prototype for the Use of Surrogate End Points in the Development of Cancer Prevention Drugs Clin. Cancer Res., June 1, 2004; 10(11): 3908 - 3918. [Full Text] [PDF]

				A. T. Chan, E. L. Giovannucci, E. S. Schernhammer, G. A. Colditz, D. J. Hunter, W. C. Willett, and C. S. Fuchs A Prospective Study of Aspirin Use and the Risk for Colorectal Adenoma Ann Intern Med, February 3, 2004; 140(3): 157 - 166. [Abstract] [Full Text] [PDF]

				J. M Herendeen and C. Lindley Use of NSAIDs for the Chemoprevention of Colorectal Cancer Ann. Pharmacother., November 1, 2003; 37(11): 1664 - 1674. [Abstract] [Full Text] [PDF]

				R. S. Sandler, S. Halabi, J. A. Baron, S. Budinger, E. Paskett, R. Keresztes, N. Petrelli, J. M. Pipas, D. D. Karp, C. L. Loprinzi, et al. A Randomized Trial of Aspirin to Prevent Colorectal Adenomas in Patients with Previous Colorectal Cancer N. Engl. J. Med., March 6, 2003; 348(10): 883 - 890. [Abstract] [Full Text] [PDF]

				M. J. Thun, S. J. Henley, and C. Patrono Nonsteroidal Anti-inflammatory Drugs as Anticancer Agents: Mechanistic, Pharmacologic, and Clinical Issues J Natl Cancer Inst, February 20, 2002; 94(4): 252 - 266. [Abstract] [Full Text] [PDF]

				J. A. O'Shaughnessy, G. J. Kelloff, G. B. Gordon, A. J. Dannenberg, W. K. Hong, C. J. Fabian, C. C. Sigman, M. M. Bertagnolli, S. P. Stratton, S. Lam, et al. Treatment and Prevention of Intraepithelial Neoplasia: An Important Target for Accelerated New Agent Development : Recommendations of the American Association for Cancer Research Task Force on the Treatment and Prevention of Intraepithelial Neoplasia Clin. Cancer Res., February 1, 2002; 8(2): 314 - 346. [Abstract] [Full Text] [PDF]

				P. A. Janne and R. J. Mayer Chemoprevention of Colorectal Cancer N. Engl. J. Med., June 29, 2000; 342(26): 1960 - 1968. [Full Text] [PDF]

				M. E. Martinez, D. Heddens, D. L. Earnest, C. L. Bogert, D. Roe, J. Einspahr, J. R. Marshall, and D. S. Alberts Physical Activity, Body Mass Index, and Prostaglandin E2 Levels in Rectal Mucosa J Natl Cancer Inst, June 2, 1999; 91(11): 950 - 953. [Abstract] [Full Text] [PDF]

				H. Li, H. A.J. Schut, P. Conran, P. M. Kramer, R. A. Lubet, V. E. Steele, E. E. Hawk, G. J. Kelloff, and M. A. Pereira Prevention by aspirin and its combination with {alpha}-difluoromethylornithine of azoxymethane-induced tumors, aberrant crypt foci and prostaglandin E2 levels in rat colon Carcinogenesis, March 1, 1999; 20(3): 425 - 430. [Abstract] [Full Text] [PDF]